Compare Abeona Therapeutics Inc (ABEO) vs Shopify Inc. (SHOP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Shopify Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Shopify Inc. trades at $117.1 (market cap $158.16B). The key difference: Shopify Inc. is far larger — about 423.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Shopify Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | SHOP | |
|---|---|---|
Market Cap | $373.32M | $158.16B |
Sector | Health | Technology |
52-Week High | $7.23 | $179.01 |
52-Week Low | $4.17 | $95.40 |
Enterprise Value | $228.22M | $152.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Shopify (SHOP) trades at $121.88, up 2.03% on the day, with a bullish technical setup showing strong moving average signals and support near $117. Revenue grew to $11.56B in 2025 with a 10.77% net margin, though valuation multiples remain elevated. Recent news highlights Bank of America reinstating a Buy rating with a $150 target, citing AI commerce tools and partnership developments.
Outlook is positive with analyst consensus at $149.10 and 63% Buy ratings, but high P/E of 117.78 poses valuation risk. Key opportunities include AI-driven growth and expanding merchant services, while risks involve competitive pressures and reliance on e-commerce trends. Cash flow trends show improving operations, supporting continued investment in innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
